COGT vs PFN Comparison

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

PIMCO Income Strategy Fund II is a closed-ended fixed income mutual fund. The company's primary investment objective is to seek high current income, consistent with the preservation of capital. The fund invests in a range of securities, such as corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, municipal bonds and notes, short-term instruments, sovereign Issues, preferred Securities and others.